The results of clinical trials of new treatments for Alzheimer disease (AD) have been consistently disappointing. Treatment failures for symptomatic individuals with mild cognitive impairment (MCI) or dementia due to AD combined with growing evidence of a perhaps decades long presymptomatic stage of AD1 have led to a focus on preventive treatments for high-risk individuals prior to any symptom onset. The hope is that treatment of preclinical AD, which is defined as the presence of AD brain pathology without evidence of cognitive impairment,2 will be the breakthrough that keeps older adults’ memories and independence intact.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Langa KM, Burke JF. Preclinical Alzheimer Disease—Early Diagnosis or Overdiagnosis? JAMA Intern Med. 2019;179(9):1161–1162. doi:10.1001/jamainternmed.2019.2629
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: